 Completed successful initial public offering and raised 46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collaboration agreement with Zentalis Pharmaceuticals Nasdaq: ZNTL to discover new product candidates for the treatment of cancer --- Presented positive pre-clinical lysosomal storage target data at annual WorldSymposiumTM --- Expect to complete proof of concept animal studies and begin IND-enabling trials in the second half of 2021 